{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:42:05Z","timestamp":1789994525206,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T00:00:00Z","timestamp":1564185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.coph.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T17:04:45Z","timestamp":1566666285000},"page":"92-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"special_numbering":"C","title":["Improving therapy of severe infections through drug repurposing of synergistic combinations"],"prefix":"10.1016","volume":"48","author":[{"given":"Yu-Shan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.07.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0426","article-title":"After 2015: infectious diseases in a new era of health and development","volume":"369","author":"Dye","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.coph.2019.07.006_bib0010","series-title":"The Top 10 Causes of Death","year":"2018"},{"key":"10.1016\/j.coph.2019.07.006_bib0015","first-page":"277","article-title":"The antibiotic resistance crisis: part 1: causes and threats","volume":"40","author":"Ventola","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.coph.2019.07.006_bib0020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ja.2013.86","article-title":"Antibiotics in the clinical pipeline in 2013","volume":"66","author":"Butler","year":"2013","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.coph.2019.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America","volume":"48","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_sbref0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2019.07.006_sbref0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrd4572","article-title":"ESKAPEing the labyrinth of antibacterial discovery","volume":"14","author":"Tommasi","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2019.07.006_bib0040","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1073\/pnas.1717160115","article-title":"Technologies to address antimicrobial resistance","volume":"115","author":"Baker","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coph.2019.07.006_sbref0045","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.coph.2019.07.006_bib0050","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.coi.2013.08.004","article-title":"Drug repurposing: a better approach for infectious disease drug discovery?","volume":"25","author":"Law","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2019.07.006_bib0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1126\/science.aaa3778","article-title":"Combating emerging viral threats","volume":"348","author":"Bekerman","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coph.2019.07.006_bib0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/1757913917743881","article-title":"WHO global priority pathogens list on antibiotic resistance: an urgent need for action to integrate One Health data","volume":"138","author":"Govindaraj Vaithinathan","year":"2018","journal-title":"Perspect Public Health"},{"key":"10.1016\/j.coph.2019.07.006_bib0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_bib0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1586\/eri.12.78","article-title":"Colistin: an update on the antibiotic of the 21st century","volume":"10","author":"Biswas","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.coph.2019.07.006_bib0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1146\/annurev.bi.46.070177.003451","article-title":"Polymyxin and related peptide antibiotics","volume":"46","author":"Storm","year":"1977","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.coph.2019.07.006_bib0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jgar.2013.03.012","article-title":"Global survey of polymyxin use: a call for international guidelines","volume":"1","author":"Wertheim","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.coph.2019.07.006_bib0085","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2019.07.006_bib0090","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2018.01.028","article-title":"Detection of colistin heteroresistance in Acinetobacter baumannii from blood and respiratory isolates","volume":"91","author":"Srinivas","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_bib0095","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkr007","article-title":"Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae","volume":"66","author":"Meletis","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2019.07.006_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","article-title":"Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study","volume":"16","author":"Liu","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_bib0105","doi-asserted-by":"crossref","DOI":"10.2807\/ese.13.47.19045-en","article-title":"Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe","volume":"13","author":"Souli","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.coph.2019.07.006_bib0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijantimicag.2016.09.014","article-title":"Synergistic combinations of polymyxins","volume":"48","author":"Lenhard","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2019.07.006_bib0115","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT01732250, Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem. 2012 Nov 22 [cited 2019 Aug 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01732250."},{"key":"10.1016\/j.coph.2019.07.006_bib0120","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT01597973, Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli. 2012 May 15 [cited 2019 Aug 20]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01597973."},{"key":"10.1016\/j.coph.2019.07.006_bib0125","first-page":"62","article-title":"Synergistic activity of colistin-containing combinations against colistin-resistant enterobacteriaceae","author":"Brennan-Krohn","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2019.07.006_bib0130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nrd4675","article-title":"Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?","volume":"14","author":"Brown","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2019.07.006_bib0135","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.bmcl.2017.08.027","article-title":"Antibiotic adjuvants \u2013 a strategy to unlock bacterial resistance to antibiotics","volume":"27","author":"Gonzalez-Bello","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2019.07.006_bib0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nchembio.559","article-title":"Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy","volume":"7","author":"Ejim","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.coph.2019.07.006_bib0145","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u201cunlikely\u201d pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI","volume":"2","author":"Schneider","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_bib0150","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1089\/mdr.2016.0196","article-title":"From breast cancer to antimicrobial: combating extremely resistant gram-negative \u201csuperbugs\u201d using novel combinations of polymyxin B with selective estrogen receptor modulators","volume":"23","author":"Hussein","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.coph.2019.07.006_bib0155","unstructured":"Hu Y, Coates A: Combination comprising zidovudine and polymyxin. US Patent 2014, US9757427B2."},{"key":"10.1016\/j.coph.2019.07.006_bib0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1042\/EBC20160058","article-title":"Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative\u2019 superbugs\u2019","volume":"61","author":"Schneider","year":"2017","journal-title":"Essays Biochem"},{"key":"10.1016\/j.coph.2019.07.006_bib0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijantimicag.2018.09.003","article-title":"An alternative strategy for combination therapy: interactions between polymyxin B and non-antibiotics","volume":"53","author":"Otto","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coph.2019.07.006_bib0170","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.123","article-title":"Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria","volume":"5","author":"Sun","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.coph.2019.07.006_bib0175","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? A review of antimicrobial synergy testing","volume":"52","author":"Doern","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coph.2019.07.006_bib0180","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination approaches to combat multidrug-resistant bacteria","volume":"31","author":"Worthington","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.coph.2019.07.006_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mib.2015.05.008","article-title":"Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution","volume":"27","author":"Bollenbach","year":"2015","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.coph.2019.07.006_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2019.07.006_sbref0195","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00077-17","article-title":"Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens?","volume":"31","author":"Domalaon","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.coph.2019.07.006_bib0200","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1128\/AAC.00508-12","article-title":"MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile","volume":"56","author":"Butler","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2019.07.006_bib0205","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/acs.jmedchem.6b00867","article-title":"Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux","volume":"59","author":"Gorityala","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2019.07.006_sbref0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fmed.2018.00267","article-title":"\u201cReal-time\u201d high-throughput drug and synergy testing for multidrug-resistant bacterial infection: a case report","volume":"5","author":"Sun","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.coph.2019.07.006_bib0215","unstructured":"Center for Disease Control and Prevention. (2019). 2014-2016 Ebola Outbreak Distribution in West Africa-Case Counts. Retrieved from https:\/\/www.cdc.gov\/vhf\/ebola\/history\/2014-2016-outbreak\/case-counts.html."},{"key":"10.1016\/j.coph.2019.07.006_bib0220","unstructured":"World Health Organization. (2019). Ebola virus disease \u2013 Democratic Republic of the Congo. Retrieved from https:\/\/www.who.int\/csr\/don\/25-july-2019-ebola-drc\/en\/."},{"key":"10.1016\/j.coph.2019.07.006_bib0225","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2015","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.coph.2019.07.006_bib0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","article-title":"Synergistic drug combination effectively blocks Ebola virus infection","volume":"137","author":"Sun","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coph.2019.07.006_bib0235","doi-asserted-by":"crossref","first-page":"S672","DOI":"10.1093\/infdis\/jiy304","article-title":"Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures","volume":"218","author":"Dyall","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coph.2019.07.006_bib0240","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(16)00320-2","article-title":"Zika virus and microcephaly: why is this situation a PHEIC?","volume":"387","author":"Heymann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2019.07.006_bib0245","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2019.07.006_bib0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A screen of FDA-approved drugs for inhibitors of Zika virus infection","volume":"20","author":"Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2019.07.006_bib0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2016.11.018","article-title":"Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay","volume":"138","author":"Adcock","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coph.2019.07.006_bib0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.coph.2019.07.006_bib0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"Yang","year":"2018","journal-title":"Cell Discov"},{"key":"10.1016\/j.coph.2019.07.006_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005717","article-title":"Efficacy and mechanism of action of low dose emetine against human cytomegalovirus","volume":"12","author":"Mukhopadhyay","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coph.2019.07.006_bib0275","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/AAC.01420-10","article-title":"Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae \u2207","volume":"55","author":"Bulik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2019.07.006_bib0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coph.2019.07.006_bib0285","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2019.07.006_bib0290","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1158\/1535-7163.MCT-14-0043","article-title":"Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor","volume":"13","author":"Pessetto","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.coph.2019.07.006_bib0295","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.tips.2013.03.004","article-title":"Challenges and opportunities of drug repositioning","volume":"34","author":"Novac","year":"2013","journal-title":"Trends Pharmacol Sci"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489219300414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489219300414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:14Z","timestamp":1761461414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489219300414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":59,"alternative-id":["S1471489219300414"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.07.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving therapy of severe infections through drug repurposing of synergistic combinations","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}